Access to advanced therapies in Europe for many patients could depend on timely and effective cross-border health care, says ARM, the Alliance for Regenerative Medicines. The issue is becoming more pressing as more advanced tissue medicinal products (ATMPs) are set to hit the market, according to the alliance, which has published recommendations to address barriers to cross-border health care and fill some of the legislative gaps.
“More and more we are going to see instances where patients need to travel to another country to get a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?